MYL9 and cancer: Treating DLD1‐CT451A1 cells with the MLCK inhibitor, ML‐7, decreased MLC2 phosphorylation (Fig. 4I and Fig. S7D, right) and promoted cancer cell vulnerability to NK cell killing (Fig. 4J).